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We report here that gemfibrozil (GFZ) inhibits axenic and intracellular growth of Legionella pneumophila
and of 27 strains of wild-type and multidrug-resistant Mycobacterium tuberculosis in bacteriological medium
and in human and mouse macrophages, respectively. At a concentration of 0.4 mM, GFZ completely inhibited
L. pneumophila fatty acid synthesis, while at 0.12 mM it promoted cytoplasmic accumulation of polyhydroxy-
butyrate. To assess the mechanism(s) of these effects, we cloned an L. pneumophila FabI enoyl reductase
homolog that complemented for growth an Escherichia coli strain carrying a temperature-sensitive enoyl
reductase and rendered the complemented E. coli strain sensitive to GFZ at the nonpermissive temperature.
GFZ noncompetitively inhibited this L. pneumophila FabI homolog, as well as M. tuberculosis InhA and E. coli
FabI.
The advent of AIDS and the emergence of many multidrug-
resistant bacterial species have led to renewed efforts to find
new antibiotics. The most commonly used antibiotics act by
blocking bacterium-specific DNA, RNA, or protein synthesis.
Mycobacterium tuberculosis is a major exception to this gener-
alization. While streptomycin, an inhibitor of bacterial protein
synthesis, was the first antibiotic to be used successfully to treat
M. tuberculosis, isoniazid (INH), an inhibitor of mycobacterial
lipid synthesis, is presently the drug most commonly used to
treat infections with this organism (2, 43). The differential
sensitivity to INH of M. tuberculosis versus mammalian cells
reflects the fact that most bacterial fatty acid synthases (type II
synthases) are comprised of discrete, separable enzymes en-
coded by separate genes, while mammalian fatty acid synthases
(type I) are dimeric proteins in which a single polypeptide
catalyzes the seven enzymatic activities of fatty acid synthesis
(21, 52).
In previous studies (45), we reported that gemfibrozil (GFZ), a
commonly prescribed and well-tolerated hypolipidemic drug, in-
hibits the export of various organic anions, including penicillin
and fluoroquinolones, from murine macrophages, thereby ele-
vating the intracellular concentration of these antibiotics and
enhancing their capacity to block intracellular growth of Lis-
teria monocytogenes. In exploring this system, we discovered
that while GFZ has no effect on axenic or intracellular
growth of Listeria monocytogenes, it inhibits axenic growth of
all Legionella pneumophila strains tested and of 5 wild-type
and 22 multidrug-resistant strains of M. tuberculosis and
inhibits intracellular growth of L. pneumophila Philadel-
phia-1 and M. tuberculosis H37RV in human and mouse
macrophages, respectively.
Both M. tuberculosis and L. pneumophila are facultative in-
tracellular pathogens that enter host macrophages by phago-
cytosis (25, 26), grow in nonlysosomal membrane-bound cyto-
plasmic vacuoles (24), have special nutrient requirements (38,
54, 55), and produce a relatively unique spectrum of mem-
brane lipids (7, 57). However, M. tuberculosis is a slow-growing
and dangerous organism with which to work. In contrast, L.
pneumophila has a relatively short doubling time (120 min) in
axenic culture medium and requires no special biohazard pre-
cautions. Therefore, we explored the mechanism(s) responsi-
ble for GFZ’s antibiotic activity in L. pneumophila, in the
expectation that a similar mechanism(s) would be operative in
M. tuberculosis.
We report here that GFZ noncompetitively inhibits L. pneu-
mophila and M. tuberculosis enoyl reductases and provide genetic
evidence consistent with the hypothesis that GFZ blocks growth
of these bacteria by inhibiting their enoyl reductases. These find-
ings, coupled with our inability to select a highly GFZ-resistant
strain of L. pneumophila, the sensitivity to GFZ of all 22 drug-
resistant M. tuberculosis strains tested, the emerging threat of
extensively drug-resistant M. tuberculosis (51), and the paucity of
* Corresponding author. Mailing address: Department of Physiol-
ogy and Cellular Biophysics, College of Physicians and Surgeons, Co-
lumbia University, 630 W 168th St., P&S11-444, New York, NY 10032.
Phone: (212) 305-3546. Fax: (212) 305-5775. E-mail: scs3@columbia
.edu.










new chemical entities for the treatment of tuberculosis, have
prompted us to describe GFZ’s antibiotic activities.
MATERIALS AND METHODS
Materials. GFZ, bezafibrate, clofibric acid, 3-(p-hydroxyphenyl)-propionic
acid, hydrochloric acid, propanol, benzoic acid, 3-hydroxy butyrate, dichloroeth-
ane, crotonyl coenzyme A (crotonyl-CoA [CCA]), and dodecyl coenzyme A
(DCA) were from Sigma-Aldrich, St. Louis, MO.
Bacterial strains and growth conditions. L. pneumophila Philadelphia-1
(27) and L. pneumophila JR32 (46) were grown in AYE broth (28) lacking
bovine serum albumin at 37°C with aeration or on ACES [N-(2-acetamido)-
2-aminoethanesulfonic acid]-buffered charcoal yeast extract agar (12). The
bacterial concentration was measured by determining the absorbance with a
Klett colorimeter. M. tuberculosis H37Rv (Pasteur Institute, Paris, France)
was grown to mid-log phase in 7H9 broth (Difco, Detroit, MI) containing
albumin-dextrose-catalase, glycerol, and 0.25% Tween 80 (Sigma, St. Louis,
MO). Mycobacterial suspensions were probe sonicated (Dismembrator 60;
Fisher Scientific, Pittsburgh, PA) for 20 s at 1.5 W to disperse clumps. Stocks
were frozen in aliquots and stored at 70°C. Aliquots were thawed and plated
to determine the number of bacilli, as previously described (34, 35).
L. pneumophila growth in human MDM. Human mononuclear cells were
purified as described previously (50). A total of 4  106 monocyte-derived
macrophages (MDM)/ml and 1  103 CFU/ml log-phase L. pneumophila organ-
isms were suspended in RPMI containing 2 mM glutamine and 10% heat-
inactivated human serum (HIHS). One-hundred-microliter aliquots of this mix-
ture were placed in a 96-well microtiter plate. The plates were centrifuged at
50  g to cosediment MDM and L. pneumophila and then incubated for 2.5 h
at 37°C. One hundred microliters of fresh medium was added, with or without
twice the indicated concentration of GFZ, clofibrate, or bezafibrate. The plates
were incubated at 37°C for the indicated times, the cells and medium were
harvested and plated on ABCYE agar plates, and the number of L. pneumophila
CFU was determined.
M. tuberculosis growth in resident mouse peritoneal macrophages. Macro-
phages were harvested from BALB/c mice, as described previously (14), and
maintained in antibiotic-free medium unless otherwise stated. Stock vials of M.
tuberculosis H37Rv were thawed, sonicated for 20 s at 1.5 W to disperse clumps,
diluted in D10 medium, and used to infect duplicate cultures of macrophages at
a multiplicity of infection (MOI) of 1 CFU per cell (1:1). The MOI was con-
firmed by plating serial dilutions of the inoculum on Middlebrook 7H10 agar
plates (Difco) containing glycerol and oleic acid-albumin-dextrose-catalase. The
viability of the cultured cells was assessed at various time points by either trypan
blue exclusion or staining of cells with TP-3 cyanine nucleic acid stain (Molecular
Probes, Eugene, OR) as described by Freeman et al. (15). Intracellular bacillary
numbers were determined by sonicating infected macrophages four times in
phosphate-buffered saline containing 0.25% Tween 80 at 1.5 W for 5 s each time.
Tenfold serial dilutions of the mycobacterial suspension were plated on Middle-
brook 7H10 agar plates as described above and incubated at 37°C for 2 to 3
weeks before counting of CFU.
Antimicrobial susceptibility. MICs of L. pneumophila were determined by
incubating triplicate samples of logarithmic-phase bacterial suspensions contain-
ing 2  106 CFU/ml in AYE broth containing serial dilutions of GFZ for 48 h
at 37°C. Growth was assessed by measuring the A600. For determination of M.
tuberculosis susceptibility, axenic cultures of different strains were suspended to
a McFarland density standard of 1 (3  108 CFU/ml) and then diluted 100-fold.
One-hundred-microliter samples of these dilutions were spotted in duplicate
onto each of the four quadrants of oleic acid-albumin-dextrose-catalase-enriched
Middlebrook agar plates; each quadrant contained 0, 0.2, 0.4, or 0.8 mM of GFZ.
The plates were incubated at 37°C for 21 days, at which time the quantity of
growth was assessed.
Transmission electron microscopy. L. pneumophila was grown for 2 days on
CYE plates, harvested, and suspended at 1010 to 1011 CFU/ml in AYE. A total
of 109 to 1010 CFU were plated on CYE agar, without or with 0.12 mM GFZ, and
incubated for 3 days at 37°C. The bacteria were harvested, pelleted, fixed by
suspension in 2.5% glutaraldehyde in 0.1 M NaPO4 buffer, pH 7.5, for 45 min at
25°C, rinsed overnight in the same buffer, rinsed twice in cacodylate buffer, pH
7.35, postfixed in 1% osmium tetroxide, rinsed successively in cacodylate buffer,
pH 7.35, and 0.1 M sodium acetate buffer, pH 6.0, incubated in 1% uranyl acetate
in 0.1 M sodium acetate buffer, pH 6.0, for 2.5 h at 4°C, dehydrated through
graded alcohols, and embedded in epoxy resin. Six-hundred-angstrom-thick sec-
tions were stained with uranyl acetate and lead citrate and examined by trans-
mission electron microscopy, using a JEOL JEM1200EX electron microscope.
Nile blue A staining. L. pneumophila was grown for 2 days on CYE plates,
harvested, and suspended at 1010 to 1011 CFU/ml in AYE. A total of 109 to 1010
bacteria were placed in CYE agar medium without or with 0.12 mM GFZ and
incubated for 3 days at 37°C. The bacteria were harvested, suspended in water,
smeared on a glass slide, and heat fixed to it. Slides were incubated in a 1%
aqueous solution of Nile blue A for 10 min at 55°C, washed with tap water,
destained for 1 min in 8% aqueous acetic acid, and air dried. Smears were
moistened with water, covered with a no. 1 glass coverslip, and examined by
fluorescence microscopy at 460 nm.
GC-MS identification and quantification of 3-HB. L. pneumophila was grown
on CYE agar for 3 days in the absence or presence of 0.12 mM GFZ, harvested,
and lyophilized. 3-Hydroxybutyrate (3-HB) propyl esters were prepared for anal-
ysis by hydrochloric acid propanolysis of lyophilized bacteria, using benzoic acid
as an internal standard, as described previously (40). A standard curve was
constructed by converting known quantities of 3-HB and benzoic acid to their
propyl esters by hydrochloric acid propanolysis. Prior to analysis, samples were
dried under a stream of nitrogen and reconstituted in ethyl acetate. Gas chro-
matography-mass spectrometry (GC-MS) analysis was performed as described
previously (53), using a Hewlett Packard 5987A GC-MS instrument equipped
with a DB-1 fused-silica capillary column (30 m by 0.2 mm), using helium as a
carrier gas at injector and source temperatures of 220°C and 200°C, respectively.
Samples were ionized by electron impact (70 eV). The abundance of ions at m/e
105 was used to measure the quantity of benzoic acid, while the abundance of
ions at m/e 87 was used to assess the quantity of 3-HB.
[14C]acetate labeling of L. pneumophila lipids. L. pneumophila was grown to
logarithmic phase in AYE broth at 37°C; 1.0-ml aliquots were pelleted and
suspended in fresh medium containing GFZ or other inhibitors at the concen-
trations indicated. [14C]acetate (specific activity, 48.9 mCi/mmol) (Amersham
Biosciences, Piscataway, NJ) was added to a final concentration of 5 Ci/ml, and
the cultures were incubated at 37°C. At different time points for up to 1 hour of
incubation, lipids were extracted from 100-l aliquots of bacterial suspension as
described by Bligh and Dyer (5). The organic layer was assayed in a scintillation
counter, and the rate of [14C]acetate labeling of lipids was determined.
ACP purification. Acyl carrier protein (ACP) from L. pneumophila was puri-
fied as described previously (41). Purified ACP migrated at 20 kDa by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as previously
described, and Edman degradation of protein eluted from this band gave an
eight-amino-acid sequence which was identical to the N-terminal sequence of L.
pneumophila ACP (STVEERVR) (lpg 1396) (10). For [14C]acetate incorpora-
tion into ACP-linked lipids, logarithmic-phase cultures of L. pneumophila were
incubated for 1 h at 37°C with 5 Ci/ml [14C]acetate in AYE, without or with 0.4
mM GFZ or other compounds. ACP was purified, and its specific activity was
determined.
Purification of L. pneumophila, E. coli, and M. tuberculosis enoyl reductases.
PCR-amplified DNA encoding L. pneumophila FabI, Escherichia coli EnvM, or
M. tuberculosis InhA was cloned into the NdeI and BamHI sites of the pET15
vector (Stratagene, La Jolla, CA) and transformed into E. coli BL21(DE3).
Mid-logarithmic-phase bacterial cultures were incubated for 1 h at 37°C in the
presence of 1 mM IPTG (isopropyl--D-thiogalactopyranoside; Sigma-Aldrich,
St. Louis, MO), pelleted, suspended in 50 mM sodium phosphate buffer, pH 8,
containing 300 mM NaCl, passed twice through a French press at 16,000 lb/in2,
and centrifuged to remove insoluble debris. The supernatant was added to a
Ni-nitrilotriacetic acid (Ni-NTA) column, and histidine-tagged proteins were
eluted with 50 mM sodium phosphate buffer, pH 8, containing 300 mM NaCl and
250 mM imidazole. The identity and purity of all proteins were confirmed by MS
of these proteins following their elution from SDS gels (e.g., see Fig. 6b).
Enoyl reductase activity. Enoyl reductase activity was assayed, as described
previously (3), by measuring the decrease in NADH absorbance at 340 nm at
room temperature, using CCA or DCA as a substrate. A standard reaction mix
contained 400 l of 100 M sodium phosphate buffer, pH 7.5, 100 m NADH,
2 g/ml purified protein, and 0.5 mM CCA or DCA. Initial velocity kinetic data
were determined at various concentrations of CCA at a fixed concentration of
NADH in either the absence or presence of GFZ (4 mM). The data were fitted
to the equation that describes noncompetitive inhibition, v  (VA)/Ka(1  I/Kis) 
A(1  I/Kii), using SigmaPlot 2000, where V is the maximum velocity, Ka is the
Michaelis constant for substrate A, and Kis and Kii are the slope and intercept
inhibition constants for inhibitor I.
Disc growth inhibition zone assay. L. pneumophila strain JR32 was trans-
formed with empty pMMB207 plasmid or with pMMB207 chloramphenicol
resistance plasmids containing wild-type L. pneumophila fabI, wild-type E. coli
fabI, or temperature-sensitive E. coli fabI (from the FT100 strain). The trans-
formed bacteria were grown overnight in AYE broth with 5 g/ml chloramphen-
icol (Sigma-Aldrich, St. Louis, MO). The next day, 0.1 ml of culture was layered
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on CYE agar plates, without or with 1 mM IPTG, and discs containing 1 mM
GFZ were added in duplicate to the plates. The plates were incubated at 37°C,
and the inhibition zone of bacterial growth was measured after 2 days.
RESULTS
GFZ inhibits growth of L. pneumophila in bacteriological
medium and in human MDM. L. pneumophila Philadelphia-1
was grown to logarithmic phase in AYE broth and further
incubated in AYE containing 0.1 to 0.4 mM GFZ. Complete
inhibition of growth required 0.4 mM GFZ (Fig. 1A). GFZ’s
MIC90 for L. pneumophila in AYE broth containing 10% heat-
inactivated human serum was 0.1 m. GFZ also inhibited
the growth of 39 other L. pneumophila strains in CYE agar, as
measured by a zone inhibition assay (data not shown). Re-
peated efforts to select spontaneous or ethyl methanesulfonate
(EMS)-induced GFZ-resistant mutants or variants of L. pneu-
mophila were uniformly unsuccessful.
GFZ inhibited growth of L. pneumophila within human
MDM (Fig. 1B) and in phorbol myristate acetate-differenti-
ated HL-60 cells (not shown). As in AYE broth, complete
inhibition of intracellular growth was observed with 0.4 mM
GFZ (Fig. 1B). GFZ at 0.4 mM was not toxic for primary
human MDM or macrophage-like cell lines, as measured by
trypan blue dye exclusion or MTT [3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide] assay, respectively (not
shown). We concluded that GFZ is bacteristatic for L. pneumo-
phila in axenic culture and in macrophages.
GFZ, like clofibrate, fenofibrate, and bezafibrate, is a fibric
acid. These compounds activate peroxisome proliferator-acti-
vated receptors (PPARs), transcriptional activators which af-
fect several metabolic pathways, including cholesterol biosyn-
thesis and -oxidation of fatty acids (23, 30, 48). To test
whether GFZ inhibited L. pneumophila growth in macro-
phages by affecting host cell functions, we compared the effects
of other fibric acids on intracellular growth of L. pneumophila.
Clofibrate and bezafibrate, even when used at 1.0 mM, were
much less effective inhibitors of L. pneumophila growth in
macrophages than GFZ at 0.4 mM (Fig. 1B). Assays in AYE
broth confirmed that the MICs for clofibrate and bezafibrate
were 0.4 mM and 1.0 mM, 4- and 10-fold higher, respectively,
than that found for GFZ. These results, our previous report
(45) that GFZ does not inhibit L. monocytogenes growth in
macrophages, and our isolation of an EMS-induced variant
(F4b) (31) that was fivefold more resistant to GFZ’s growth
inhibitory effect in both axenic media and macrophages suggest
that GFZ inhibits L. pneumophila’s growth in macrophages by
acting on the bacterium, not on the host cell.
GFZ inhibits the growth ofM. tuberculosis in bacteriological
medium and in mouse peritoneal macrophages. The intracel-
lular bacterial pathogen of greatest medical and economic
importance is M. tuberculosis. Therefore, we examined GFZ’s
effect on the growth of 27 M. tuberculosis strains, 22 of which
were resistant to one or more antitubercular drugs. GFZ at 0.4
mM completely inhibited growth of 14 of these M. tuberculosis
strains, and at 0.8 mM it inhibited growth of all of them,
regardless of their profile of resistance to other antibiotics,
including INH (Table 1).
In contrast, 1 to 1.2 mM GFZ was required to block the
growth of M. tuberculosis in mouse peritoneal macrophages by
80% (Fig. 2). GFZ’s inhibitory effect persisted for as long as
the drug was maintained in the medium. Removal of GFZ
from the medium resulted in resumption of M. tuberculosis
growth (not shown), confirming both the viability of macro-
phages in medium containing this concentration of GFZ and
that GFZ is bacteristatic for M. tuberculosis. In contrast, INH
at 10 and 1 g/ml (0.07 M and 0.007 M, respectively) killed
	99% of M. tuberculosis cells, INH at 0.1 g/ml held the M.
tuberculosis concentration relatively constant, and INH at 0.01
and 0.005 g/ml had little or no inhibitory effect. Moreover,
GFZ at 1 to 1.2 mM neither enhanced nor reduced the capac-
ity of 1 to 0.005 g/ml INH to inhibit M. tuberculosis growth in
macrophages when the two drugs were used in combination
(not shown).
GFZ distinguishes Nocardia sp. from atypical mycobacteria.
In addition to L. pneumophila and M. tuberculosis, 0.4 mM
FIG. 1. GFZ inhibits axenic growth of L. pneumophila. (A) L.
pneumophila growth in the absence (F) or presence of 0.1 mM ()
(28% inhibition), 0.2 mM (f) (76% inhibition), or 0.4 mM (E) (88%
inhibition) GFZ, as measured by changes in absorbance using a Klett
colorimeter. (B) GFZ inhibits the growth of L. pneumophila in human
MDM. CFU of L. pneumophila were measured at the indicated times
after infection. Macrophages were maintained in medium alone (F) or
in medium containing 0.4 mM GFZ () (	100% inhibition), 1.0 mM
bezafibrate (E) (86% inhibition), or 1.0 mM clofibric acid (f) (98%
inhibition). Both panels report one experiment representative of three
that yielded similar results.
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GFZ inhibited the growth of other human pathogens (e.g.,
Nocardia sp., Staphylococcus epidermidis, and Staphylococcus
aureus) (data not shown). However, it had little or no effect on
the growth of atypical mycobacteria, suggesting that it might be
used in clinical microbiology to distinguish Nocardia sp. from
atypical mycobacteria.
GFZ stimulates accumulation of PHB in L. pneumophila. L.
pneumophila maintained on CYE agar containing 0.12 mM
GFZ developed very large, often irregularly shaped electron-
lucent inclusions (Fig. 3b) compared to the relatively small
round inclusions found in L. pneumophila maintained in the
absence of GFZ (Fig. 3a). Similar electron-lucent inclusions
have been reported to contain polyhydroxybutyrate (PHB) (9,
42), a polymer of 3-HB (29, 36). Nile blue A, a dye that stains
PHB-containing granules (39), stained these inclusions (Fig.
3d), and GC-MS analysis of extracts of L. pneumophila main-
tained on CYE without or with 0.12 mM GFZ confirmed that
GFZ-treated L. pneumophila contained 50-fold more 3-hy-
droxybutyryl-propyl ester (3-HBPE) than untreated bacteria
(42.5 
 7.5 mg 3-HBPE/mg protein versus 0.75 
 0.75 mg
3-HBPE/mg protein). Since 3-HB, the precursor of PHB, is an
intermediate in fatty acid synthesis (1, 21), these results sug-
gested that GFZ inhibits a step in fatty acid synthesis and led
us to investigate this possibility.
GFZ inhibits [14C]acetate incorporation into L. pneumo-
phila lipids. L. pneumophila cells incubated in medium con-
taining [14C]acetate incorporate the acetate primarily into lip-
ids (55). Therefore, we tested GFZ’s effect on [14C]acetate
TABLE 1. Susceptibility of various M. tuberculosis strains to GFZ
Strain
Drug resistance profilea No. of colonies/quadrant
S I R E K O C No GFZ GFZ at 0.2 mM(50 g/ml)
GFZ at 0.4 mM
(100 g/ml)
GFZ at 0.8 mM
(200 g/ml)
O80154 S S S S S S S 100–500 50–99 0 0
H37RV S S S S S S S 100–500 100–500 1 0
CDC K S S S S S S S 100–500 50–99 6 0
MH S S S S S S S 100–500 100–500 50–99 0
MTB25177 S S S S S S S 	1,000 	1,000 50–99 0
H52578 R S S S S S S 100–500 100–500 0 0
CM R S S S S S S 	1,000 	1,000 50–99 0
NM S R S S S S S 	1,000 18 0 0
CDC P S RL S S S S S 100–500 100–500 0 0
CDC T S RL S S S S S 100–500 100–500 0 0
CDC D S RL S S S S S 100–500 100–500 0 0
S15674 S R S S S S ND 100–500 50–99 10 0
F16285 S R S S S S S 100–500 50–99 10 0
CDC N S S R S S S S 100–500 50–99 0 0
M23294 S S S R S S S 100–500 50–99 4.5 0
M41151 S S S R S S S 100–500 50–99 7.5 0
CDCL R S R S S S S 100–500 	1,000 50–99 0
JJ S R R S S S S 100–500 7 0 0
F5260 S R R S S S S 100–500 45 0 0
O80711 R R R S S S S 100–500 50–99 6 0
T30234 S R R R S S S 100–500 50–99 0 0
W19521 S R R R S S S 100–500 50–99 0 0
W54410 R R R R S S S 100–500 35 0 0
RF R R R R S S S 	1,000 100–500 0 0
O81256 R R R R S S S 100–500 50–99 0 0
T45777 R R R R R R R 100–500 100–500 50–99 0
AA R R R R R R R 100–500 100–500 50–99 0
a Sensitivity (S) or resistance (R) to antibiotics. Abbreviations: S, streptomycin at 2 mg/ml; I, INH at 1 mg/ml; R, rifampin at 1 mg/ml; E, ethambutol at 5
mg/ml; K, kanamycin at 6 mg/ml; O, ofloxacin at 4 mg/ml; C, ciprofloxacin at 2 mg/ml; RL, low-level resistance to INH at 0.2 mg/ml; ND, not done.
FIG. 2. GFZ inhibits the growth of M. tuberculosis in mouse peri-
toneal macrophages. Macrophages were infected with M. tuberculosis
and incubated in D10 medium without or with GFZ. Data are shown
for controls (no GFZ) (f), cells receiving 1.2 mM GFZ for 8 days (),
controls (no GFZ) receiving fresh medium without GFZ on day 3 (Œ),
cells receiving 1.2 mM GFZ, with a switch to fresh medium without
GFZ on day 3 (‚), controls (no GFZ) receiving fresh medium without
GFZ on day 5 (F), and cells with 1.2 mM GFZ, with a switch to fresh
medium without GFZ on day 5 (E). Data are the averages for dupli-
cate cultures from one experiment representative of three that yielded
similar results.
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incorporation into a chloroform-methanol (5) extract of log-
phase (5  108 CFU/ml) L. pneumophila cells incubated in
AYE medium containing [14C]acetate and various concentra-
tions of GFZ. [14C]acetate incorporation into the chloroform-
methanol extract was inhibited 19%, 38%, and 76% by GFZ at
0.05 mM, 0.1 mM, and 0.2 mM, respectively, and was almost
completely blocked by 0.4 mM GFZ (Fig. 4), the same con-
centration that completely blocked L. pneumophila growth in
this medium (Fig. 1A). We compared the effectiveness of GFZ
with similar concentrations of known inhibitors of fatty acid
synthesis. Cerulenin (0.45 mM), a -ketoacylsynthase inhibi-
tor, and INH (0.5 mM), an enoyl reductase inhibitor, inhibited
[14C]acetate incorporation into L. pneumophila lipids 99%
and 76%, respectively. Thin-layer chromatographic analysis
of these extracts confirmed these results and showed that GFZ
decreased labeling of all lipids to approximately the same ex-
tent (data not shown). GFZ’s inhibitory effect on lipid synthe-
sis is consistent with the hypothesis that it blocks fatty acid
synthesis.
GFZ inhibits fatty acid elongation on L. pneumophila ACP.
To determine GFZ’s effect on assembly of fatty acids on ACP,
we purified ACP from L. pneumophila cultures that were in-
cubated for 1 h in [14C]acetate-containing medium without or
with 0.4 mM GFZ. GFZ inhibited [14C]acetate association
with ACP 80% (Fig. 5). Parallel analyses of ACP purified
from L. pneumophila incubated in [14C]acetate-containing me-
dium with compounds that share high structural similarity to
GFZ, such as 3-(p-hydroxyphenyl)-propionic acid (3-HPA)
and clofibric acid, showed that these compounds had only
modest (21% and 31%, respectively) inhibitory effects on
[14C]acetate association with ACP (Fig. 5A). Other known
fatty acid synthesis inhibitors, such as INH, cerulenin, and the
FIG. 3. GFZ promotes PHB accumulation in L. pneumophila.
Transmission electron microscopy was performed on L. pneumophila
Philadelphia 1 grown on CYE agar in the absence (a) or presence (b)
of 0.12 mM GFZ. (c and d) Fluorescence micrographs of Nile blue
A-stained L. pneumophila grown on CYE agar in the absence (c) or
presence (d) of 0.12 mM GFZ. Magnification, 10,000 (a), 20,000
(b), or 1,000 (c and d).
FIG. 4. GFZ inhibits acetate incorporation into L. pneumophila
lipids. L. pneumophila was incubated with [14C]acetate in AYE me-
dium in the absence or presence of 0.04 to 0.4 mM GFZ. At different
time points, [14C]acetate incorporation into the chloroform-methanol-
soluble fraction was measured. Data are the averages for duplicate
cultures from one experiment representative of three that yielded
similar results.
FIG. 5. GFZ inhibits fatty acid elongation on L. pneumophila ACP.
Logarithmic-phase L. pneumophila cells were incubated for 1 h at 37°C
in AYE medium containing [14C]acetate in the absence or presence of
0.4 mM GFZ, 1 mM clofibric acid (CFA), 1 mM 3-HPA, 0.01 mM
triclosan (TRI), 0.2 mM cerulenin (CER), or 0.7 mM INH. ACP was
purified from these cells, and its protein and radioactive contents were
measured, all as described in Materials and Methods.
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commonly used enoyl-ACP reductase inhibitor triclosan, in-
hibited [14C]acetate association with ACP by 70%, 89%, and
86%, respectively (Fig. 5B).
To confirm that the ACP labeling observed in the absence of
GFZ reflected incorporation of [14C]acetate into nascent fatty
acids and not its biosynthetic conversion into amino acids sub-
sequently used for ACP synthesis, we blocked L. pneumophila
protein synthesis with kanamycin and incubated these kana-
mycin-treated cells with [14C]acetate. ACP isolated from L.
pneumophila incubated in medium containing [14C]acetate and
kanamycin had about the same specific activity as ACP iso-
lated from L. pneumophila incubated in kanamycin-free me-
dium containing [14C]acetate (586 cpm/g protein versus
520 cpm/g protein). Moreover, GFZ inhibited [14C]acetate
incorporation into ACP to about the same extent in kana-
mycin-treated cells as it did in cells incubated in the absence
of kanamycin (148 cpm/g protein versus 156 cpm/g pro-
tein). These results support the hypothesis that GFZ inhibits
fatty acid synthesis.
Identification and purification of L. pneumophila enoyl re-
ductase. The findings that GFZ stimulates PHB accumulation,
blocks fatty acid synthesis, and inhibits [14C]acetate association
with ACP in kanamycin-treated L. pneumophila cells strongly
suggested that it inhibits one of the enzymes in the fatty acid
elongation cycle. Potential targets were -ketoacylsynthetase,
-hydroxydecenoyl dehydrase, and enoyl reductase. FabI enoyl
reductase, the rate-limiting enzyme in E. coli fatty acid synthe-
sis (18), seemed the most likely candidate, since inhibition of
this enzyme in E. coli by long-chain fatty acids stimulates ac-
cumulation of 3-hydroxybutyryl-ACP (19), and 3-hydroxybu-
tyryl-ACP can be converted to -hydroxybutyryl-CoA, the pre-
cursor of PHB. To examine this possibility, we sought a
putative fabI homolog in L. pneumophila.
E. coli strain FT100 (3) carries a mutation in the enoyl
reductase homolog gene, envM. FT100 carries a tempera-
ture-sensitive (TS) E. coli enoyl reductase (56). We trans-
formed E. coli FT100 with DNA from a wild-type L. pneu-
mophila library by using the shuttle vector pMMB207 and
sought colonies that grew at 42°C, the restrictive tempera-
ture for E. coli FT100. Since fabI is an essential gene in E.
coli, we expected to identify L. pneumophila genes encoding
a protein(s) with complementing enoyl reductase activity.
Using this strategy, we identified a 1,375-bp fragment from
L. pneumophila which complemented the FT100 TS strain
for growth at 42°C. Sequence analysis of this 1,375-bp DNA
fragment demonstrated that it includes an 804-bp open reading
frame (GenBank accession number AE017354; lpg1854) (10) en-
coding a putative 268-amino-acid protein with 58% identity and
78% similarity to the E. coli EnvM enzyme and 31% identity and
57% similarity to InhA, the INH-sensitive enoyl reductase from
M. tuberculosis (Fig. 6A).
Kinetic characteristics of L. pneumophila enoyl-CoA reduc-
tase. The putative L. pneumophila fabI gene was cloned into
the pET15b expression vector, generating a protein with an N-
terminal six-histidine tag. The protein was purified to homogene-
ity using nickel-NTA column chromatography (Fig. 6B).
Enoyl reductases catalyze the NADH-dependent reduction
of unsaturated fatty acyl groups covalently bound to the pan-
tothenate moiety of ACP. One mole of NAD is generated for
each mole of crotonyl-ACP reduced. Accordingly, we assessed
the enoyl reductase activity of the L. pneumophila protein
purified by nickel-NTA chromatography by measuring the de-
FIG. 6. (A) Aligment of enoyl-CoA reductase amino acid sequences of L. pneumophila (FabI), E. coli (EnvM), and M. tuberculosis (InhA).
(B) SDS-PAGE and Coomassie blue staining of purified enoyl reductases from L. pneumophila (lane 1), E. coli (lane 2), and M. tuberculosis
(lane 3).
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creased absorbance of NADH at 340 nm as it was oxidized to
NAD (4), and its substrate, CCA, was converted to butyryl-
CoA. Kinetic analyses indicated that the L. pneumophila en-
zyme had a Km of 1.8 
 0.2 mM (Fig. 7A) and a Vmax of 55 

3 nmol/min/g for CCA in the presence of 100 M NADH.
The Km and Vmax for NADH in the presence of 0.5 mM CCA
were estimated to be 18 
 3 M and 22 
 1 nmol/min/g,
respectively (Fig. 7B).
GFZ inhibits L. pneumophila FabI enoyl-CoA reductase. To
assess GFZ’s effect on L. pneumophila FabI, we measured
NADH oxidation in the presence of constant concentrations of
enzyme and substrate and concentrations of GFZ varying from
0.5 to 4 mM. All experiments were performed with a submaxi-
mal Vmax substrate concentration. The graphs show data from
multiple experiments in which 100% enzyme activity ranged
from 10 to 20 nmol/minute/g protein (Fig. 8 and Fig. 9). GFZ
inhibited L. pneumophila FabI 35% at 0.5 mM and 60% at 4
mM (Fig. 8). Clofibric acid, which has only a modest inhibitory
effect on L. pneumophila growth in macrophages at 1 mM (Fig.
1), inhibited FabI activity by 30% at 4 mM (Fig. 8). 3-HPA did
not detectably inhibit L. pneumophila FabI at concentrations
of 4 mM, consistent with the result shown in Fig. 5.
The apparent Km of FabI for CCA did not change much in
the presence of 4 mM GFZ, while the apparent Vmax value
decreased (Fig. 7A). Very similar results were obtained for
NADH saturation (Fig. 7B). For both CCA and NADH, the Kii
FIG. 7. Kinetic characteristics of L. pneumophila enoyl-CoA reduc-
tase. The activity of purified L. pneumophila FabI was assessed by
measuring the decrease in absorbance at 340 nm as NADH was oxi-
dized to NAD in the absence (F) or presence (E) of 4 mM GFZ.
(A) The dependence of enzyme activity on the concentration of sub-
strate (crotonyl-CoA) was determined in the presence of 100 M
NADH. (B) The dependence of enzyme activity on the concentration
of NADH was determined in the presence of 0.5 mM crotonyl-CoA.
Data are the averages for duplicate cultures from one experiment
representative of three that yielded similar results.
FIG. 8. GFZ is a more potent inhibitor of L. pneumophila FabI
than clofibric acid or 3-HPA. The inhibitory effects of 0.5 to 4 mM
GFZ (f), clofibrate (Œ), and 3-HPA (F) on enoyl-CoA reductase
activity of purified L. pneumophila FabI were assessed by measuring
the decrease in absorbance at 340 nm of NADH (100 M) in the
presence of 2 g/ml purified protein and 0.5 mM CCA. Data are the
averages for duplicate cultures from one experiment representative of
three that yielded similar results.
FIG. 9. GFZ inhibits purified enoyl-CoA reductases from L. pneu-
mophila, E. coli, and M. tuberculosis. The activities of enoyl-CoA re-
ductases from L. pneumophila (FabI) (F), E. coli (EnvM) (f), and M.
tuberculosis (InhA) (Œ) were measured by monitoring the rate of
decrease in absorbance at 340 nm in the presence of constant concen-
trations of enzyme and substrate (0.5 mM CCA for FabI and EnvM
and 0.5 mM DCA for InhA) at the indicated GFZ concentrations.
Data are the averages for duplicate cultures from one experiment
representative of three that yielded similar results.
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and Kis were not distinguishable, indicating that FabI binds
GFZ with similar affinities in the presence and absence of
substrate. The Kii and Kis versus CCA were 4.1 
 0.8 mM and
5 
 1 mM, and those versus NADH were 1.4 
 0.3 mM and
4 
 3 mM, respectively. Linear transformation of the enzyme
activity data suggests that GFZ is a noncompetitive inhibitor of
FabI. These findings are reported in preliminary form in U.S.
patent applications 5,422,372 and 6,713,043.
GFZ inhibits E. coli and M. tuberculosis enoyl-CoA reducta-
ses. Since E. coli and M. tuberculosis enoyl-CoA reductases are
58% and 31% identical in sequence to L. pneumophila FabI,
respectively, we tested GFZ’s effect on these enzymes. The E.
coli fabI and M. tuberculosis inhA genes were cloned into
pET15b, generating enoyl reductase proteins with an N-termi-
nal six-histidine tag, and the proteins were purified as de-
scribed in Materials and Methods (Fig. 6B). With CCA as a
substrate, the apparent Km for E. coli FabI was 2.9 
 0.2 mM,
which is very similar to the Km reported for E. coli FabI by
others (4), and the Vmax was 98 
 4 nmol/min/g.
GFZ inhibited the E. coli and M. tuberculosis proteins to the
same degree as L. pneumophila FabI (Fig. 9). Although E. coli
growth was not inhibited by GFZ, the drug behaved as a
noncompetitive inhibitor of purified E. coli FabI. The Kii and
Kis versus CCA were calculated to be 2.8 
 0.4 mM and 2.9 

0.4 mM, respectively. GFZ also inhibited InhA (Fig. 9). InhA
is reported to prefer longer acyl-CoA substrates than those
used by E. coli and L. pneumophila enoyl reductases (6, 44) and
has a lower specific activity than the E. coli and L. pneumophila
enzymes. For InhA enzymatic assays, we used 1 mM DCA as a
substrate. Maximum InhA activity was 283 pmol/min/g pro-
tein. Due to its low activity, this enzyme was not characterized
further.
GFZ inhibits purified E. coli enoyl reductase but does not
inhibit E. coli growth. Purified E. coli enoyl reductase is as
sensitive to GFZ as L. pneumophila FabI. Thus, it was surpris-
ing and of interest that GFZ did not inhibit E. coli growth.
Ideally, we would have liked to have transfected a FabI-nega-
tive E. coli strain with L. pneumophila FabI to explore E. coli’s
resistance to GFZ. However, E. coli fabI is an essential gene,
and it was not possible to knock it out. Hence, we transfected
wild-type L. pneumophila with a plasmid containing either L.
pneumophila or E. coli fabI under the control of an IPTG-
inducible promoter. Discs containing 1 mM GFZ were added
in duplicate to CYE agar plates (without or with 1 mM IPTG)
containing a wild-type L. pneumophila strain transformed with
pMMB207 empty plasmid or pMMB207 plasmid containing
either wild-type L. pneumophila fabI, wild-type E. coli fabI, or
TS E. coli fabI (from strain FT100). The plates were incubated
at 37°C for 2 days, the radius of the growth inhibition zone was
measured, and the area of growth inhibition was calculated.
The area of growth inhibition for L. pneumophila overexpress-
ing L. pneumophila fabI was 29% smaller than that for the
same L. pneumophila strain containing empty vector (Table 2)
when IPTG was present but was only 6% smaller in IPTG’s
absence. The fact that the zone of inhibition decreased to a
much greater extent in the presence of IPTG than in its ab-
sence confirmed that it resulted from FabI overexpression. E.
coli FabI expressed in L. pneumophila also increased the GFZ
resistance of transfected L. pneumophila in an IPTG-depen-
dent manner, but the area of inhibition in the presence of
IPTG was only half that for L. pneumophila transfected with L.
pneumophila FabI (16.5% versus 32%). Whether this reflects
less efficient expression or function of E. coli FabI than of L.
pneumophila FabI in L. pneumophila cannot be determined
from this experiment. What is evident, however, is that E. coli
FabI increases L. pneumophila’s resistance to GFZ. TS E. coli
FabI (FT100), which has only 30% of the enoyl reductase
activity of wild-type FabI (FT101) at 30°C (3) and is virtually
inactive at 37°C, did not enhance the resistance of L. pneumo-
phila to GFZ at 37°C, demonstrating that enzymatically active
FabI is required to overcome GFZ’s growth-inhibitory effect.
These results are consistent with the hypothesis that FabI is a
target for GFZ in vivo.
DISCUSSION
GFZ inhibits axenic growth of 40 different Legionella sp.
strains, 27 M. tuberculosis strains (5 antibiotic-sensitive and
22 antibiotic-resistant strains, including 16 strains resistant to
INH), and several other human pathogens, such as Nocardia
sp. and S. aureus (not shown). It inhibits the growth of L.
pneumophila and M. tuberculosis in human and mouse macro-
phages (Fig. 1 and 2). At submaximal concentrations (e.g., 0.12
mM), GFZ markedly reduces acetate incorporation into L.
pneumophila lipids (Fig. 5) and promotes PHB accumulation
in this bacterium (Fig. 4). Although it is not the focus of this
study, the finding that GFZ stimulates PHB accumulation is
noteworthy and suggests that GFZ, and perhaps other com-
pounds with similar activities, shunts intermediates in fatty acid
synthesis into PHB. Accordingly, GFZ may be useful for stim-
ulating L. pneumophila, and perhaps other bacteria, to produce
commercially valuable polyhydroxyalkanoates (17, 33).
We cloned an L. pneumophila protein that is homologous to
the E. coli enoyl reductase FabI and that expresses enoyl-CoA
reductase activity (Fig. 6). This L. pneumophila enoyl reductase
complemented growth of an E. coli strain expressing a temper-
ature-sensitive FabI protein at a nonpermissive temperature.
Hence, we termed this L. pneumophila protein Legionella FabI.
Fatty acid synthesis in bacteria is tightly coordinated with
membrane phospholipid formation and with other plasma
membrane components, and substances that inhibit fatty acid
synthesis block bacterial growth (58). Enoyl-ACP reductase
executes the final step of fatty acid elongation and is a key
regulator of this pathway (18, 21). GFZ is a noncompetitive
inhibitor of E. coli, L. pneumophila, and M. tuberculosis enoyl
reductases (Fig. 5, 7, 8, and 9). Thus, it is evident why it inhibits
L. pneumophila and M. tuberculosis growth. What remains un-
resolved is the mechanism by which E. coli resists GFZ’s
TABLE 2. Growth inhibition zones of L. pneumophila and E. coli
cells overexpressing enoyl reductase
Gene on plasmid
pMMB207
Inhibition area (mm2) Difference in area
of inhibition
(1 mM IPTG/no
IPTG)No IPTG 1 mM IPTG
Vector only 706.5 
 23.5 684.5 
 69.5 3
L. pneumophila fabI 663.0 
 91.0 452.0 
 19.0 32
E. coli fabI 660.5 
 45.5 551.0 
 21.0 16.5
TS E. coli fabI 730.5 
 24.0 754.5 
 48.5 3
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growth-inhibitory effects. Aside from the conjecture that E. coli
is impermeable to GFZ or highly efficient at pumping it out of
the cytoplasm, we have no explanation for its GFZ resistance.
Diazaborines, triclosan, and INH are all enoyl-ACP-reduc-
tase inhibitors, but they have different mechanisms of action
(20, 21). While mutations in InhA at or near residues involved
in NADH binding confer resistance of M. tuberculosis to INH
(2, 43), INH-resistant M. tuberculosis strains were as sensitive
to GFZ as INH-sensitive strains (Table 1). Moreover, overex-
pression of L. pneumophila or E. coli FabI in L. pneumophila
increased L. pneumophila’s resistance to GFZ (Table 2). Sim-
ilarly, transfection of E. coli with a multicopy vector encoding
FabI increased the resistance of the resulting strain to triclosan
(22). These findings are consistent with the hypothesis that
GFZ inhibits L. pneumophila and M. tuberculosis growth by
inhibiting their respective enoyl reductases. The finding that
GFZ is equally effective in suppressing growth of INH-sensi-
tive and INH-resistant M. tuberculosis strains suggests that
GFZ interacts with InhA at a different site from that for INH.
Both E. coli FabI and FabH are inhibited by elevated intra-
cellular levels of long-chain acyl-ACP (3, 58). GFZ inhibited
[14C]acetate incorporation into L. pneumophila ACP by80%
(Fig. 5), suggesting that it did not promote accumulation of
long-chain acyl-ACP. For this reason, we think it unlikely that
GFZ indirectly inhibits L. pneumophila growth by elevating the
intracellular concentration of long-chain acyl-ACP.
Several bacterial species metabolize carboxylates by ligating
them to CoA (13, 16, 32, 49). Ciprofibrate, which like GFZ is
a carboxylate, is converted to ciprofibroyl-CoA in rat and mar-
moset livers (8, 11). Thin-layer chromatographic analyses of
extracts of L. pneumophila incubated with 0.4 mM GFZ and/or
[3H]GFZ showed no evidence of any GFZ derivative (e.g.,
GFZ-AMP or GFZ-CoA) (data not shown). These negative
findings, taken together with the findings that GFZ directly
inhibits the activity of FabI isolated from L. pneumophila and
E. coli and of InhA from M. tuberculosis and that overexpres-
sion of L. pneumophila or E. coli FabI in L. pneumophila
increases L. pneumophila resistance to GFZ, are most consis-
tent with the hypothesis that GFZ inhibits axenic growth of L.
pneumophila and M. tuberculosis by directly blocking FabI- and
InhA-mediated fatty acid synthesis, respectively.
GFZ is reported to inhibit fatty acid chain elongation in rat
liver microsomes (47). However, it is unknown whether GFZ,
like ciprofibrate, is converted to GFZ-CoA in the mammalian
liver. If it is, its inhibitory effect on mammalian fatty acid
synthesis may be due to GFZ-CoA’s effect on mammalian
enoyl-CoA reductase, not to GFZ’s direct effect on these en-
zymes. It is also unknown whether GFZ is converted to a CoA
derivative by macrophages and whether such CoA derivatives
have the capacity to permeate either the cytoplasmic vacuoles
in which L. pneumophila and M. tuberculosis reside and grow
within macrophages or the walls and membranes of these bac-
teria when they are resident within their respective membrane-
bound compartments. Without resolution of these issues, we
cannot be certain whether the mechanism(s) by which GFZ
inhibits fatty acid synthesis in L. pneumophila and M. tubercu-
losis in bacteriological media is the same as that by which it
blocks fatty acid elongation in mammalian microsomes and/or
growth of L. pneumophila and M. tuberculosis in macrophages.
Nonetheless, the findings that GFZ, an approved, widely used,
and generally well-tolerated drug, inhibits axenic growth of
multiple L. pneumophila strains and of multiple pan-drug-sen-
sitive and multidrug-resistant M. tuberculosis strains and blocks
the growth of these pathogens in macrophages maintained in
serum-containing medium suggest that it may have similar
activity against them in vivo. While the concentration of GFZ
required to inhibit growth of these bacteria is greater than that
currently used to lower blood lipid levels clinically, it is possible
that administration of higher levels of GFZ might be thera-
peutically beneficial and/or that more potent congeners of this
drug could be identified.
The ability of M. tuberculosis to grow in mouse macrophages
is reportedly dependent on its capacity to scavenge fatty acids
from these cells (37). The findings that GFZ blocks intracel-
lular growth of L. pneumophila and that both GFZ and INH
block intracellular growth of M. tuberculosis suggest that these
bacteria may shunt host cell fatty acids directly into bacterial
membrane phospholipids, in addition to using them as oxidiz-
able substrates for generating ATP and reduced pyridine nu-
cleotides.
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